Skip to main content
Eine offizielle Website der Europäischen UnionOffizielle Website der EU
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Inhalt archiviert am 2024-06-18

Rational molecular Assessments and Innovative Drug Selection

Ziel

Cervical cancer (CC) is the second most common cause of cancer deaths in women worldwide. The main objective of the RAIDs project is to use this model system which is accessible to repeat biopsies to learn how to stratify patients into targeted therapies. The patients’ tumors will be classified into molecular subtypes based on their molecular profile by use of high-throughput technologies (sequencing, RPPA) combined with integrative bioinformatics analysis. Stratification is a learning process which will need constant readaptation. It will rely on prognostic and predictive biomolecular information gained from patients who will receive either standard therapy (the cognitive cohort) or patients who receive (first generation) targeted therapy. Bioinformatics will be an essential tool to allow integrative genome/proteome analysis and provide functional interpretation of the results at each step. Machine learning techniques will be used to select the most reliable biomarkers. These tools will be used to predict response to cc treatment or progression. Moreover, systems biology approaches will be used to unravel the gene regulatory networks and signaling pathways involved in the tumor progression and should be helpful to select predictive biomarkers and putative drug targets.
Tumor material will be sampled before and following standard therapy or therapeutic HPV vaccination and/or novel targeted drug treatments. Clinical annotation by imaging methods as well as through biomarkers will have quality control procedures and relevant statistical models will be applied.
RAIDS is a multidisciplinary approach integrating genomic studies, protein arrays, viral genotyping and immunohistochemical investigations on CC cells and tissues between academic clinical centers and SME’s .
The project is expected to provide new tools for early diagnosis and targeted treatments exploited by SMEs and to accelerate innovation of CC therapy and improve quality of life.

Wissenschaftliches Gebiet (EuroSciVoc)

CORDIS klassifiziert Projekte mit EuroSciVoc, einer mehrsprachigen Taxonomie der Wissenschaftsbereiche, durch einen halbautomatischen Prozess, der auf Verfahren der Verarbeitung natürlicher Sprache beruht. Siehe: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

Sie müssen sich anmelden oder registrieren, um diese Funktion zu nutzen

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2012-INNOVATION-1
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

CP-FP - Small or medium-scale focused research project

Koordinator

INSTITUT CURIE
EU-Beitrag
€ 1 651 811,20
Adresse
RUE D ULM 26
75231 Paris
Frankreich

Auf der Karte ansehen
Region
Ile-de-France Ile-de-France Paris
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Beteiligte (17)

Diese Seite teilen Diese Seite in sozialen Netzwerken teilen

Herunterladen Den Inhalt der Seite herunterladen

Letzte Aktualisierung: 6 September 2024

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/304810/de

European Union, 2025